RxDoctor Payments Data

Marbella Tran, MD

Family Medicine · Lubbock, TXNPI 1215129705

Payments from drug & device makers

$10,115in general payments, 2019–2025

Across 672 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$769
  • Amgen$749
  • Abbott$527
  • Otsuka America Pharmaceutical, Inc.$431
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$10,00099%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,115 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$198,781
Medicare patients
373
Services billed
3,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide164$184,344
JardianceEmpagliflozin72$86,262
OzempicSemaglutide51$55,512
ProliaDenosumab19$31,715
JanuviaSitagliptin Phosphate23$28,411
RexultiBrexpiprazole12$27,336
FarxigaDapagliflozin Propanediol25$23,474
TrulicityDulaglutide12$22,890
EliquisApixaban13$14,558
LinzessLinaclotide26$14,547
MyrbetriqMirabegron15$14,527
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,419
Levothyroxine Sodium485$5,364
Dexlansoprazole DrDexlansoprazole19$5,258
Colesevelam Hcl11$3,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,130$207,233176 claims
Boehringer IngelheimJardiance$14$86,26272 claims
Novo NordiskOzempic$769$55,51251 claims
AmgenProlia$749$31,71519 claims
MerckJanuvia$19$28,41123 claims
Otsuka America Pharmaceutical, Inc.Rexulti$431$27,33612 claims
AstraZenecaFarxiga$252$23,47425 claims
AbbVieLinzess, Synthroid$2,088$17,51583 claims
PfizerEliquis, Paxlovid$342$15,98829 claims
Astellas Pharma US IncMyrbetriq$394$14,52715 claims
GSKTrelegy Ellipta$48$11,41915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →